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Senescent cells accumulate in numerous tissues with 
aging and at sites of pathogenesis of multiple chronic 
diseases [1, 2]. Small numbers of senescent cells can 
cause extensive local and systemic dysfunction due to 
their pro-inflammatory senescence-associated secretory 
phenotype (SASP) [3]. For example, transplanting only 
2X105 senescent ear chondroblasts or preadipocytes 
around knee joints induces osteoarthritis in mice, while 
injecting similar numbers of non-senescent cells does 
not [4]. Clearing senescent cells by activating a drug-
inducible “suicide” gene in progeroid or naturally-aged 
mice alleviates a range of age- and disease-related  pheno- 
 
types, including sarcopenia, frailty, cataracts, adipose 
tissue dysfunction, insulin resistance, and vascular 
hyporeactivity [5-7]. 
 
To decrease the burden of senescent cells in non-
genetically-modified individuals, we used a hypothesis-
driven approach to identify senolytic compounds, which 
preferentially induce apoptosis in senescent rather than 
normal cells [8, 9]. Our approach was based on the 
observation that senescent cells are resistant to 
apoptosis [10]. This suggested that senescent cells either 
have reduced engagement of pro-apoptotic pathways 
that serve to protect them from their own pro-apoptotic 
SASP or they have up-regulated pro-survival pathways 






















Senescent  cells  accumulate with  aging  and  at  sites of pathology  in multiple  chronic diseases.  Senolytics  are
drugs that selectively promote apoptosis of senescent cells by temporarily disabling the pro‐survival pathways
that enable senescent cells to resist the pro‐apoptotic, pro‐inflammatory factors that they themselves secrete.
Reducing  senescent  cell  burden  by  genetic  approaches  or  by  administering  senolytics  delays  or  alleviates
multiple  age‐  and  disease‐related  adverse  phenotypes  in  preclinical  models.  Reported  senolytics  include





and A1155463 are  senolytic  in HUVECs and  IMR90  cells, but not preadipocytes. These agents may be better
candidates for eventual translation into clinical interventions than some existing senolytics, such as navitoclax,
which is associated with hematological toxicity. 
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[8]. We demonstrated the latter to be the case and 
identified senescence-associated pro-survival pathways 
based on expression profiling of senescent vs. non-
senescent cells. We confirmed the requirement of these 
pathways for survival of senescent but not non-
senescent cells by RNA interference. These pathways 
included pro-survival networks related to PI3K/ AKT, 
p53/ p21/  serpines, dependence receptor/tyrosine 
















































We tested drugs that target these pro-survival pathways. 
We initially reported that the dependence receptor/ 
tyrosine kinase inhibitor, dasatinib (D) and the 
flavonoid, quercetin (Q), are senolytic in vitro and in 
vivo. D and Q induced apoptosis in senescent primary 
human preadipocytes and HUVECs, respectively. 
Combining D+Q broadened the range of senescent cells 
targeted, and, in some instances, proved synergistic in 
















































Figure 1.  Fisetin  targets  senescent  cells.  (a)  Structure  of  fisetin.  (b‐d)  Fisetin  is more  effective  in  reducing  viability  (ATPLite)  of
senescent  HUVECs  than  IMR90  cells  or  primary  human  preadipocytes.  Proliferating  or  senescent  cells  were  exposed  to  different
concentrations of fisetin for 3 days. The red lines denote ATPLite intensities on day 0 of senescent and non‐senescent cells, both set to
100%. HUVEC  and  IMR90  data  are means±SEM  of  5  replicates  at  each  drug  concentration.  Preadipocyte  data  are means±SEM  of  5
replicates  from  each  of  4  different  subjects  at  each  concentration.  (e‐g)  Fisetin  selectively  reduces  senescent  but  not  proliferating
HUVECs and IMR90 cell numbers (crystal violet). The red lines denote cell numbers at plating on day 0 of senescent and non‐senescent
cells,  both  set  to  100%. HUVEC  and  IMR90  data  are means±SEM  of  5  replicates  at  each  drug  concentration.  Preadipocyte  data  are
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vascular, frailty-related, osteoporotic, neurological, 
radiation-induced, and other phenotypes and disorders 
in chronologically aged, progeroid, and high fat-fed 
atherosclerosis-prone mice, consistent with our 
observations in mice from which senescent cells had 
been removed by inducing the suicide gene in 
transgenic INK-ATTAC mice [5-8]. Expanding upon 
our findings with Q, we tested if the related flavonoid, 
fisetin (Fig. 1A), is senolytic. Fisetin is widely available 
as a nutritional supplement and has a highly favorable 
side-effect profile. 
 
Based on our earlier hypothesis-driven identification of 
senolytic drugs and identification of the BCL-2 pro-
survival pathway as one of the “Achilles’ heels” of 
senescent cells [8], we and others simultaneously 
reported that the BCL-2/ BCL-W/ BCL-XL inhibitor, 
navitoclax (ABT263; N), is senolytic [11, 12]. Like D 
and Q, N is senescent cell type-specific, being effective 
in inducing apoptosis in HUVECs but not human 
preadipocytes. This is consistent with our initial report, 
in which we observed that RNA interference against 
BCL-XL is senolytic in HUVECs, but not primary 
human preadipocytes [8]. We also found that the related 
BCL-2 family inhibitor, TW-37, is not senolytic. TW-
37, unlike N, does not target BCL-XL. Others confirmed 
that N targets senescent cells, but Bcl-2 family 
inhibitors that do not target BCL-XL are not senolytic 
[12, 13]. We therefore tested if the relatively specific 
BCL-XL inhibitors, A1331852 and A1155463 (Figs. 2A 
& 3A, respectively) [14], are senolytic. Unlike N, these 
agents do not target BCL-2. Consequently, A1331852 
or A1155463 may cause less BCL-2-induced neutrophil 




To assess if fisetin is senolytic, we cultured primary 
human preadipocytes, HUVECs, and IMR90 cells and 
exposed these cells to 10Gy radiation (senescent cells) 
or sham-irradiated them (control cells). Fisetin (Fig. 1a), 
like its analog quercetin [8], selectively reduced 
viability (ATPLite; Fig. 1b-d) and numbers (crystal 
violet; Fig. 1e-g) of senescent HUVECs, but not IMR90 
cells or primary human preadipocytes. It induced 
apoptosis in senescent HUVECs, confirmed by 
caspase3/7 activity assay (Fig. 1h). The concentrations 
at which fisetin caused caspase activity to increase, 
viability as assessed by ATPLite to decrease, and cell 
numbers as assessed by crystal violet to decrease to 
below those levels at the time the cells had originally 
been plated were: 0.5 µM, 5 µM, and 10 µM, 
respectively. The different concentration thresholds may 
reflect activation of caspases at lower concentrations or 
earlier times than those required to interfere with 
viability and cell death. 
The BCL-XL inhibitors, A1331852 (Fig. 2a) and 
A1155463 (Fig. 3a), selectively reduced viability (Figs. 
2b-d & 3b-d, respectively) and survival (Figs. 2e-g & 
3e-g, respectively) of senescent HUVECs and IMR90 
cells, but not senescent preadipocytes. A1331852 and 
A1155463 increased ATP in proliferating preadipocytes 
(Figs. 2b &3b). As with fisetin, apoptosis was induced 
by A1331852 and A1155463, as demonstrated by 
caspase3/7 activity assays (Figs. 2h-i & 3h-i, 
respectively). Also as with fisetin, concentrations at 
which A1331852 and A1155463 began to affect caspase 
< ATPLite < crystal violet. The observation that 
senescent HUVECs were more sensitive to the BCL-XL 
inhibitors than human preadipocytes is consistent with 
our findings using RNA interference in the first article 




We found that fisetin and the BCL-XL inhibitors, 
A1331852 and A1155463, are senolytic in vitro, 
inducing apoptosis in senescent, but not non-senescent 
HUVECs. This adds three new agents to the emerging 
repertoire of senolytics reported since early 2015, which 
currently includes D, Q, N, and piperlongumine [8, 11, 
12, 15]. 
 
Fisetin (3,3’,4’,7-tetrahydroxyflavone) is a member of 
the flavonoid family, a group of naturally occurring 
polyphenolic compounds [16]. It is present in low 
concentrations in many fruits and vegetables such as 
apples, persimmon, grapes, onions, and cucumbers, 
with the highest concentration found in strawberries 
(160µg/g) [16]. The average dietary intake of naturally 
occurring fisetin was approximately 0.4 mg/day in a 
Japanese study [17]. Due to it’s being hydrophobic, 
fisetin penetrates cell membranes and accumulates 
within cells to exert antioxidant effects [18]. Other 
promising biological activities of fisetin include anti-
hyperglycemic, anti-hyperlipidemic, anti-inflammatory, 
neurotrophic, and anti-carcinogenic effects [16, 19-26]. 
Fisetin promotes apoptosis in human breast cancer 
MCF-7 cells by activating caspases-7,8,&9 without 
causing apoptosis in non-tumorigenic cells [25]. Fisetin 
has a plasma terminal half-life of just over 3 hours in 
mice, with its metabolites being excreted in feces and 
urine. It alleviates dysfunction in animal models of 
chronic disease, including diabetic kidney disease and 
acute kidney injury [19, 20, 27-29], attributes consistent 
with those expected from a senolytic agent [9]. Here we 
demonstrate that fisetin is indeed senolytic in senescent 
HUVECs, but not in senescent IMR-90 cells or human 
preadipocytes. Interestingly, the fisetin concentrations 
achieved in a mouse study without causing toxicity 
(2.7- 349.4 µM) [30] are similar to and even higher than 
those we found to be senolytic in cultured HUVECs. 













































The intrinsic mitochondrial apoptosis pathway is 
inhibited by the BCL-2 (B-cell lymphoma-2) protein 
family. BCL-2, BCL-XL (BCL-2 related protein, long 
isoform), and MCL-1 (myeloid cell leukemia-1) bind 
the BH3 motifs of pro-apoptotic proteins, including 
BIM (BCL-2 interacting mediator of cell death), BAK 
(BCL-2 antagonist/killer), and BAX (BCL-2 associated 
X protein). N, which targets the BCL-2 family 
members, BCL-2, BCL-W, and BCL-XL, is senolytic 
[11, 12]. However, drugging of BCL-2-related proteins 
can involve serious side-effects, including depletion of 













































Among the BCL-2-related proteins, BCL-XL is a 
particularly attractive therapeutic target, since it is 
required for survival of senescent HUVECs, as 
demonstrated in our RNA interference studies [8]. 
Although the BCL-2 inhibitors have a number of side-
effects, A1331852 and A1155463 are relatively 
selective BCL-XL inhibitors [14] and appear less likely 
to cause neutropenia than N, making them potentially 
better candidates for eventual translation into clinical 
applications. A1331852 and A1155463 are senolytic in 
HUVECs and IMR-90 cells but not primary human 
preadipocytes. We noted that these drugs increased 
Figure  2. A1331852  targets  senescent  cells.  (a)  Structure  of  A1331852.  (b‐d)  A1331852  is more  effective  in  reducing  viability





cells,  both  set  to  100%. HUVEC  and  IMR90  data  are means±SEM  of  5  replicates  at  each  drug  concentration.  Preadipocyte  data  are
means±SEM  of  5  replicates  from  each  of  4  different  subjects  at  each  concentration.  (h‐i)  A1331852  induces  apoptosis  in  senescent
HUVECs  and  IMR90  cells.  HUVECs were  treated with  A1331852  for  12h  and  then  caspases‐3&7 were  assayed  using  a  luminescent
substrate. A1331852 (1 nM) induced apoptosis in senescent cells by caspase 3/7 assay. 
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cellular ATP levels significantly in senescent human 
preadipocytes, but not HUVECs, through an as yet 
unknown mechanism. 
 
We predict many more senolytic drugs will appear at an 
accelerating pace over the next few years. Initially, most 
are likely to be based on re-purposed drugs or natural 
products. Increasingly, new senolytics will likely be 
derived using medicinal chemical approaches based on 
optimizing properties of the repurposed agents. 
Consistent with this, it appears that small changes in the 












































senolytic activity, such as in the case of D vs. imatinib, 
with the latter not being senolytic, or N vs. the closely-
related agent, TW-37. Conversely, we speculate that 
small structural changes to repurposed senolytic drugs 
could enhance senolytic activity, with increases in the 
percent and range of types of senescent cells eliminated, 
as well as better stability, bioavailability, and side-effect 
profiles. 
 
Many more senolytics will likely be discovered in the 
near future, with some targeting the senolytic pathways 













































Figure  3. A1155463  targets  senescent  cells.  (a)  Structure  of  A1155463.  (b‐d)  A1155463  is more  effective  in  reducing  viability





cells,  both  set  to  100%. HUVEC  and  IMR90  data  are means±SEM  of  5  replicates  at  each  drug  concentration.  Preadipocyte  data  are
means±SEM  of  5  replicates  from  each  of  4  different  subjects  at  each  concentration.  (h‐i)  A1155463  induces  apoptosis  in  senescent
HUVECs  and  IMR90  cells.  HUVECs were  treated with  A1155463  for  12h  and  then  caspases‐3&7 were  assayed  using  a  luminescent
substrate. A1155463 (1 nM ) induced apoptosis in senescent cells by caspase 3/7 activity assay. 
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interference approaches. These include dependence 
receptor/ tyrosine kinase- (e.g., D), PI3K/ AKT/ 
metabolic- (e.g., Q and fisetin), BCL-2- (e.g., N, 
A1331852, and A1155463), p53/ p21/ serpine (PAI-
1&2)-, and HIF-1α-related pathways [8]. We also 
predict that many or most new agents will target 
particular types of senescent cells, such as senescent 
cells originating from different cell types or varying in 
the mechanisms through which senescence was 
induced. Consistent with this, fisetin, a flavonoid that is 
related to Q, was senolytic for senescent HUVECs but 
not preadipocytes, as was the case for Q [8]. 
Furthermore, we previously found by RNA interference 
that BCL-XL is needed for survival of senescent 
HUVECs, but not human preadipocytes. Consistent 
with this observation is the fact that neither A1331852 
nor A1155463 are senolytic for human preadipocytes. 
This cell type specificity could mean that particular 
senolytic drugs or combinations will be more effective 
for some age- or senescence-related indications than 
others. For example, it could be speculated that 
combining fisetin, A1331852, or A1155463 with D or a 
related senolytic active against senescent preadipocytes 
might be more effective than fisetin, A1331852, or 
A1155463 alone for obesity-related indications, a point 
that needs to be studied in appropriate pre-clinical 
models. 
 
Some side effects of senolytic drugs may extend across 
the class. These include delays in skin wound healing, 
since senescent cells may facilitate certain phases of 
wound resolution and tissue repair [32]. At higher 
concentrations than those that cause apoptosis in 
senescent cells, fisetin, A1331852, and A1155463 may 
be cytostatic in proliferating cells. This inhibition of 
proliferation is not associated with apoptosis in non-
senescent cells until yet higher concentrations are 
reached. This suggests that, like most drugs, these 
agents will have a concentration window over which 
they are effective and safe, with lower concentrations 
failing to be senolytic and higher concentrations likely 
being toxic. Other serious side effects of senolytics as a 
class have not become apparent so far in preclinical 
studies using these agents or in studies of clearance of 
senescent cells in transgenic mice expressing drug-
inducible “suicide” proteins in their senescent cells. 
However, it is likely that more class-specific side 
effects will emerge over time. An advantage of seno-
lytics over drugs that must be present continuously to be 
effective is that senolytics likely can be administered 
intermittently, reducing the opportunity for side effects to 
occur. 
 
Other effects and side effects of individual senolytics 
are likely to be drug-specific. Fisetin has few known 
side effects so far [33], unlike BCL-2 inhibitors. Fisetin 
is metabolized by glucuronidation [30], so it could 
potentiate effects of warfarin, necessitating reduction in 
the dose of warfarin and other drugs. On balance, 
fisetin, D, Q, and piperlongumine appear to have strong 
potential for becoming orally-active senolytic agents for 
clinical use, or at least to become scaffolds that can be 
optimized using medicinal chemical approaches for use 
as oral agents. N and possibly A1331852 and A1155463 
could see use as injected senolytic agents, allowing 
effective local senolytic concentrations to be achieved 
while reducing the likelihood of systemic side effects. 
A1331852 and A1155463 could be safer than N since 
they have less effects on neutrophil levels. 
Alternatively, BCL-2 inhibitors could be used systemi-
cally at lower doses, possibly in combination with other 
senolytic drugs. 
 
Combining senolytics with distinct, additive 
mechanisms of action is an attractive option that needs 
to be investigated further in preclinical studies. 
Consistent with the potential value of this approach, the 
combination of D+Q has broader senolytic activity than 
either agent alone [8] and the combination of D and 
A1331852 is more effective than either drug alone in 
inducing apoptosis in chronic myeloid leukemia cells 
[34]. Furthermore, combinations of senolytics with 
other agents that target fundamental aging mechanisms, 
such as 17α-estradiol, that act through mechanisms 
other than targeting senescent cells [35] may prove to 
be more effective than individual agents and could 
flatten side-effect profiles. 
 
Senolytics have potential for delaying, preventing, or 
alleviating a number of age-related phenotypes and 
chronic diseases, including diabetes, osteoporosis, 
frailty, cardiovascular disease, pulmonary fibrosis, and 
cancers, among others [2, 6-8]. Clinical trials are 
needed to determine the safety and efficacy of these 
drugs before routine clinical use is considered. This 
includes agents that are available over the counter as 
nutritional supplements. Now that we have shown that 
fisetin, A1331852, and A1155463 are senolytic in vitro, 
studies are needed to determine if these new additions 
to the growing number of senolytic agents reduce 
senescent cell burden in vivo and alleviate dysfunction 
in aged animals and pre-clinical animal models of age- 
and senescence-related diseases. 
 
MATERIALS AND METHODS 
 
Isolation and cell culture of primary human 
preadipocytes 
 
Abdominal subcutaneous adipose tissue for primary 
preadipocyte isolation was obtained during intra-
abdominal surgery from 4 healthy, lean subjects 
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undergoing surgery to donate a kidney (male; age 
45.2±2.4 [mean ± SEM] years), who had given 
informed consent. The cells were passaged 4 population 
doublings. Preadipocytes are also known as adipose-
derived stem cells or fat cell progenitors (for detailed 
discussion of nomenclature, see [36]). The protocol was 
approved by the Mayo Clinic Foundation Institutional 
Review Board for Human Research. Detailed 
descriptions of preadipocyte isolation and cell culture 
conditions are in our publications [8, 11, 37].  
 
Human Umbilical Vein Endothelial Cell (HUVEC) 
culture 
 
Human umbilical vein endothelial cells (HUVECs) 
were purchased from Lonza (Lonza, Walkersville, MD) 
and grown in Clonetics Endothelial Cell Growth 
Medium-2 (EGM-2; Lonza) according to the manufac-
turer’s protocol. 
 
IMR90 cell culture 
 
IMR90 cells were purchased from ATCC (Manassas, 
VA) and grown in Dulbecco’s Modified Eagle’s 
Medium with 10% fetal bovine serum according to the 
guide provided by ATCC. 
 
Induction of cellular senescence 
 
HUVECs, IMR90 cells, or human primary 
preadipocytes at passage 4 were radiated with 10 Gy to 
induce senescence or were sham-radiated. Preadipo-
cytes were senescent by 20 days after radiation, 
IMR90 cells after 20 days, and HUVECs after 10 days, 
with 90% or more cells positive for senescence-
associated β-galactosidase activity and by increased 
SASP factor expression by ELISA (IL-6, MCP-1), as 
in [6, 8, 11]. 
 
Sources of agents and addition to cultures 
 
Fisetin powder was purchased from Sigma (cat# F 
4043, St. Louis, MO). A 60 mM stock solution of fisetin 
in DMSO was stored at -80°C until use. This stock 
solution was then further diluted in DMSO and added to 
culture media, so that the final fisetin concentrations in 
culture media shown in each figure were achieved with 
0.1% DMSO:medium (v/v). A1331852 and A1155463 
were purchased as powders from Selleckchem (cat# 
S7801 and cat# S7800, respectively; Houston, TX). A 
50 mM stock solution for each drug of A1331852 or 
A1155463 was prepared in DMSO and stored at -80°C 
until use This stock solution was then further diluted in 
DMSO and added to culture media, so that the final 
A1331852 or A1155463 concentrations in culture media 





Cell viability was measured using an ATPLite Kit (cat# 
6016941; PerkinElmer, Waltham, MA). The assay was 
performed according to the manufacturer’s instructions. 
Luminescence was read using a multi scan plate reader 
(Fisher, Waltham, MA). 
 
Crystal violet assay 
 
Viable cell numbers were measured by staining with 
crystal violet. Cells were washed twice with PBS, 
incubated with PBS containing 4% paraformaldehyde 
for 15 minutes at room temperature, and then stained 
with 0.1% crystal violet for 30 minutes at room 
temperature. Cells were washed with deionized water 
and staining intensity was measured at λ540 using a 
multi scan plate reader (Fisher, Waltham, MA). 
 
Caspase 3/7 assay 
 
Induction of apoptosis was measured with a Caspase-
Glo® 3/7 Assay kit (Promega, Cat.# G8091, Madison, 
WI) 12 hours after exposing cells to different 
concentrations of drugs. The activity of caspase3/7 was 
assessed by luminescence intensity using a multi scan 




One- and two-way ANOVA tests were conducted using 
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